Champions Oncology, Inc. Forecast, price target & analysts
Champions Oncology, Inc. Target price 2026 - Analyst rating & recommendation
Champions Oncology, Inc. Classifications & Recommendation
Champions Oncology, Inc. Price Target
| Target Price | $12.24 |
| Price | $4.79 |
| Potential |
155.53%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target Champions Oncology, Inc. 2027 .
The average Champions Oncology, Inc. target price is $12.24.
This is
155.53%
register free of charge
$12.60
163.05%
register free of charge
$12.12
153.03%
register free of charge
|
|
| A rating was issued by 7 analysts: 6 Analysts recommend Champions Oncology, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Champions Oncology, Inc. stock has an average upside potential 2027 of
155.53%
register free of charge
|
Sales and Margin forecast 2027, 2028 to 2030
| Apr '26 |
2027 Estimates |
|
|---|---|---|
| Revenue Million $ | 59.43 | 66.57 |
| 4.37% | 12.01% | |
| EBITDA Margin | 0.59% | 2.18% |
| 94.83% | 270.16% | |
| Net Margin | -1.99% | 2.13% |
| 124.05% | 207.28% |
3 Analysts have issued a sales forecast Champions Oncology, Inc. 2027 . The average Champions Oncology, Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Champions Oncology, Inc. EBITDA forecast 2027. The average Champions Oncology, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2026 | $350k | 94.61% |
|---|---|---|
| 2027 |
$1.5m
315.43%
unlock
|
|
EBITDA Margin
| 2026 | 0.59% | 94.83% |
|---|---|---|
| 2027 |
2.18%
270.16%
unlock
|
|
3 Champions Oncology, Inc. Analysts have issued a net profit forecast 2027. The average Champions Oncology, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2026 | $-1.2m | 125.11% |
|---|---|---|
| 2027 |
$1.4m
220.34%
unlock
|
|
Net Margin
| 2026 | -1.99% | 124.05% |
|---|---|---|
| 2027 |
2.13%
207.28%
unlock
|
|
Earnings per share, P/E ratio and EV/sales Estimates 2027, 2028 to 2030
| Apr '26 |
2027 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.09 | 0.10 |
| 127.27% | 211.11% | |
| P/E | 46.96 | |
| EV/Sales | 0.93 |
3 Analysts have issued a Champions Oncology, Inc. forecast for earnings per share. The average Champions Oncology, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2026 | $-0.09 | 127.27% |
|---|---|---|
| 2027 |
$0.10
211.11%
unlock
|
|
P/E ratio
| Current | -59.88 | 290.08% |
|---|---|---|
| 2027 |
46.96
178.43%
unlock
|
|
Champions Oncology, Inc....
Current Champions Oncology, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Craig-Hallum |
Locked
➜
Locked
|
Locked | Mar 12 2025 |
| Craig-Hallum |
Locked
➜
Locked
|
Locked | Dec 12 2024 |
| Craig-Hallum |
Locked
➜
Locked
|
Locked | Sep 12 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Craig-Hallum:
Locked
➜
Locked
|
Mar 12 2025 |
|
Locked
Craig-Hallum:
Locked
➜
Locked
|
Dec 12 2024 |
|
Locked
Craig-Hallum:
Locked
➜
Locked
|
Sep 12 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
